Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant

Read more

Media coverage

Press releases

Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant

Read more

Media coverage

Taiwan Bio debuts its cell therapy platforms and strives to start another clinical trial next year for a new drug to treat critical limb ischemia.

on 21 September 2022, in Media coverage

Taiwan Bio debuts its cell therapy platforms and strives to start another clinical trial next year for a new drug to treat critical limb ischemia.

on 21 September 2022, in Media coverage

Taiwan Bio has been listed on the Emerging Stock Board (ESB). With its dual-track strategy, Taiwan Bio is optimistic about the outlook

on 07 September 2022, in Media coverage

Taiwan Bio has been listed on the Emerging Stock Board (ESB). With its dual-track strategy, Taiwan Bio is optimistic about the outlook

on 07 September 2022, in Media coverage

Taiwan Bio, focused on cell therapies, will be listed on Pioneer Stock Board (PSB) of Emerging Stock Market (ESM) tomorrow

on 12 May 2022, in Media coverage

Taiwan Bio, focused on cell therapies, will be listed on Pioneer Stock Board (PSB) of Emerging Stock Market (ESM) tomorrow

on 12 May 2022, in Media coverage

Taiwan Bio, specialized in development of mesenchymal stem cell therapy products, is expected to be listed on Emerging Stock Market (ESM) in May

on 22 April 2022, in Media coverage

Taiwan Bio, specialized in development of mesenchymal stem cell therapy products, is expected to be listed on Emerging Stock Market (ESM) in May

on 22 April 2022, in Media coverage

Media coverage

Taiwan Bio debuts its cell therapy platforms and strives to start another clinical trial next year for a new drug to treat critical limb ischemia.

on 21 September 2022, in Media coverage

Taiwan Bio debuts its cell therapy platforms and strives to start another clinical trial next year for a new drug to treat critical limb ischemia.

on 21 September 2022, in Media coverage

Taiwan Bio has been listed on the Emerging Stock Board (ESB). With its dual-track strategy, Taiwan Bio is optimistic about the outlook

on 07 September 2022, in Media coverage

Taiwan Bio has been listed on the Emerging Stock Board (ESB). With its dual-track strategy, Taiwan Bio is optimistic about the outlook

on 07 September 2022, in Media coverage

Taiwan Bio, focused on cell therapies, will be listed on Pioneer Stock Board (PSB) of Emerging Stock Market (ESM) tomorrow

on 12 May 2022, in Media coverage

Taiwan Bio, focused on cell therapies, will be listed on Pioneer Stock Board (PSB) of Emerging Stock Market (ESM) tomorrow

on 12 May 2022, in Media coverage

Taiwan Bio, specialized in development of mesenchymal stem cell therapy products, is expected to be listed on Emerging Stock Market (ESM) in May

on 22 April 2022, in Media coverage

Taiwan Bio, specialized in development of mesenchymal stem cell therapy products, is expected to be listed on Emerging Stock Market (ESM) in May

on 22 April 2022, in Media coverage

Press releases

Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant

on 13 December 2023, in Press releases

Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant

on 13 December 2023, in Press releases

Press releases

Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant

on 13 December 2023, in Press releases

Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant

on 13 December 2023, in Press releases